Sovaldi (sofosbuvir) / Gilead 
Welcome,         Profile    Billing    Logout  
 18 Diseases   22 Trials   22 Trials   2501 News 


«12...1011121314151617181920...2122»
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Trial initiation date:  the Pulmonary Safety of Antihepatitis C Treatment (clinicaltrials.gov) -  Mar 30, 2020   
    P=N/A,  N=50, Not yet recruiting, 
    Initiation date: Dec 2019 --> Jun 2020
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. (Pubmed Central) -  Mar 28, 2020   
    The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Sofosbuvir use for yellow fever: a new perspective treatment. (Pubmed Central) -  Mar 26, 2020   
    Since 2016, Brazil has experienced two outbreaks, and collective health measures have been adopted to contain these grievances. However, published data about the drug sofosbuvir against flaviviruses are promising, suggesting the relevance of conducting future clinical trials.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Interpreting Viral Deep Sequencing Data with GLUE. (Pubmed Central) -  Mar 22, 2020   
    In three further cases, it confirmed that the sofosbuvir-resistant NS5B substitution S282T was absent. This suggests the direct read translation approach implemented is of value for interpreting viral deep sequencing data.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Journal:  Polymorphism in IFNL3/IL28B gene and risk to non-cirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. (Pubmed Central) -  Mar 20, 2020   
    Our data revealed that the TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) exhibited significant association with chronic HCV genotype 3 infection when compared with controls. The results of treatment response showed that CC (major) genotype of IFNL3 (rs12979860) and TT (major) genotype of IFNL3 (rs8099917) are associated with likelihood of achieving a higher sustained virological response (SVR), to combined daclatasvir and sofosbuvir therapy, in genotype 3 infected HCV patients, whereas the individuals with TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) are more susceptible to chronic HCV infection and treatment relapse, suggesting a role of IFNL3 (rs12979860) and (rs8099917) in the treatment outcome of combined daclatasvir and sofosbuvir therapy in chronic HCV genotype 3 infection.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Preclinical, Journal:  CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro. (Pubmed Central) -  Mar 19, 2020   
    These data provide evidence that CCR5 modulation could have a significant effect on HCV replication in an in vitro system. Further evaluation of the role of CCR5 inhibition in clinical settings may be warranted.
  • ||||||||||  Journal:  Developments in the treatment of HCV genotype 3 infection. (Pubmed Central) -  Mar 14, 2020   
    This also includes patients infected with GT3 subtypes such as GT3b where multiple DAA-resistant substitutions occur naturally. Unless new drugs with non-overlapping drug-resistant profiles are discovered, perhaps a pegIFN-based therapy may be beneficial in select patient populations with high-level multiple DAA-resistant substitutions.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C TREATED UNDER A NEW STANDARD OF CARE () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1931;    
    OBJECTIVES : The approval of sofosbuvir in December 2013 and subsequent introduction of other direct-acting antivirals changed the paradigm for treating Hepatitis C (HCV), but posed a challenge to payers seeking to anticipate characteristics of patients receiving treatment and their risk of outcomes...CONCLUSIONS : Drug innovations can significantly shift the characteristics of patient populations receiving treatment, due to both clinical and access-related factors. In cases where these factors can be measured, it may be possible to restrict the population on a prior SoC to more closely resemble that on the new SoC, thus leveraging historical RWE to represent a new SoC in forward-looking decisions.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Preclinical, Journal:  Developing animal models of Zika virus infection for novel drug discovery. (Pubmed Central) -  Mar 5, 2020   
    One promising example is Sofosbuvir, which protected mice models against Zika pathogenesis by preventing vertical transmission. Importantly, there is a lack on exploration on the long-term effects of Zika Congenital Syndrome, as well as the possible ways to treat its sequelae.
  • ||||||||||  netupitant (Ro 67-3189) / Helsinn, Otsuka, doxorubicin hydrochloride / Generic mfg., Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Successes, failures, and future prospects of prodrugs and their clinical impact. (Pubmed Central) -  Mar 4, 2020   
    For example, newer platelet aggregation inhibitors could signal the end of the warfarin era with their demanding treatment follow-up...This strategy employs the design of artificial enzymes to activate prodrugs at specific sites. Agents designed for use in DEPT medicine can be directed at antibodies, genes, viruses, and clostridia.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] IMPACT OF HCV CLEARANCE ON NK CELLS AND HIV TRANSCRIPTION IN COINFECTED SUBJECTS ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_922;    
    Downregulation of NK cell activation was observed immediately after HCV clearance although some markers rebounded one year later, in concomitance with increased transcriptional activity of HIV reservoir. This may be reflecting the priming of NK cells by the residual HIV transcription and might point out a role for NK cells in shaping HIV persistence.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] HIV/HCV VS HCV: PLASMA AND LIVER VIRAL DYNAMICS AND IP-10 LEVELS ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_320;    
    We enrolled 10 people with chronic genotype 1a HCV infection without cirrhosis in a clinical trial of Sofosbuvir and Velpatasvir for 12 weeks; 5 people had virologically suppressed HIV on antiretrovirals...However, residual immune activation appears to persist despite virologic suppression of both viruses. While this may not have different implications for virologic cures, there may be persistent effects on liver disease progression in HIV/HCV co-infection.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells. (Pubmed Central) -  Feb 22, 2020   
    The aryloxyl phosphoramidate ProTide of 2'-C-methyluridine outperformed the hepatitis C virus (HCV) drug sofosbuvir in suppression of viral titers and protection from cytopathic effect, while the former compound's triphosphate active metabolite was better incorporated by purified ZIKV NS5 polymerase over time. These findings suggest both a nucleobase and ProTide group bias for the anti-ZIKV activity of nucleoside analogue ProTides in a disease-relevant cell model.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] HEPATITIS C TREATMENT ON A SHOESTRING ([VIRTUAL]) -  Feb 17, 2020 - Abstract #CROI2020CROI_134;    
    The Malaysian government opted to grant a compulsory license to import affordable generic sofosbuvir at $237 per course, compared to $11,200 with sofosbuvir...As demonstrated by countries on track for HCV elimination, the main challenges are detecting the 80% of people unaware of their status and providing universal access to DAAs, essential to halt HCV transmission. Simplification of HCV models of care and DAA affordability are key determinants for countries to launch elimination programs.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Sofosbuvir induced leucocytoclasic vasculitis: a case report. (Pubmed Central) -  Feb 16, 2020   
    No abstract available Vasculitis appeared after the beginning of Sofosbuvir and, even though it was treated with different medications proved to be effective, it disappeared only after the conclusion of the therapy, giving a strong evidence to be a drug eruption.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal, Real-World Evidence:  Prevalence of TSH dysfunction among sofosbuvir-treated HCV infected patients: a real-world clinical experience. (Pubmed Central) -  Feb 14, 2020   
    We observed thyroid dysfunctions in both pegylated-interferon experienced and DAA drug experienced patients but the prevalence of hyperthyroidism was found significantly higher in patients treated with interferon-based regimen as compared to interferon-free regimens. This high prevalence of hypothyroidism in HCV patients post-treatment highlights the need of regular periodic screening of patients during the treatment.
  • ||||||||||  voxilaprevir (GS-9857) / Gilead, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. (Pubmed Central) -  Feb 9, 2020   
    P4
    Our study demonstrates safety, efficacy and functional benefit of DCV/SOF treatment in KTR with chronic HCV infection. We provide data on rescue strategies for treatment failures due to present RAVs and amelioration of hepatic function and glucose tolerance.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Effect of direct-acting antivirals on corrected QT interval and cardiac functions in patients with chronic hepatitis C virus infection. (Pubmed Central) -  Feb 8, 2020   
    The current national protocol of HCV infection treatment with direct-acting antiviral agents used in Egyptian patients has a good cardiac safety profile. Such treatments have no effect on QTc interval, left and right ventricular functions except for a decrease in RV GLS in those with no liver cirrhosis and a reduction in lateral mitral E' velocity in those with liver cirrhosis both remained within the normal reference range.